电影蜜桃熟了,国产精品99久久99久久久,精品国产不卡在线观看免费

泛昔洛韋

NMR下載 COA and HPLC MSDS下載
names：
Famciclovir
CAS號：
104227-87-4
MDL Number： MFCD00866964
MF(分子式)： C14H19N5O4 MW(分子量)： 321.33
EINECS:630-411-6 Reaxys Number:
Pubchem ID:3324 Brand:BIOFOUNT

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)是一種鳥嘌呤類似物抗病毒藥，用于治療各種皰疹病毒感染。; IC50值：參見噴昔洛韋;目標：HSV泛昔洛韋是活性抗病毒化合物噴昔洛韋的二乙?；?-脫氧類似物，可能在治療中使用由皰疹病毒家族引起的感染。泛昔洛韋，一種合成的無環(huán)鳥嘌呤衍生物，是一種前藥，口服后可迅速代謝為生物利用度高的抗病毒化合物噴昔洛韋[2]。體外：泛昔洛韋可快速，劑量依賴性地抑制病毒復制并減少丙氨酸。氨基轉(zhuǎn)移酶（ALT），在500 mg tid治療組中療效最佳。在整個治療期間，HBV DNA的降低一直保持。在治療期間，ALT也穩(wěn)定下降。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000717-100mg	100mg	99.74%	￥ 1251.00	￥ 1251.00		2-3天	- +	￥ 0.00
YZM000717-50mg	50mg	99.74%	￥ 696.15	￥ 696.15		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	泛昔洛韋(104227-87-4);法昔洛為; 法昔洛韋;1,3-丙二醇，2-（2-（2-氨基-9H-嘌呤-9-基）乙基）-二乙酸酯(酯); 9-（4-乙酰氧基-3-（乙酰氧基甲基）丁-1-基）-2-氨基嘌呤;BRL 42810;BRL-42810;BRL42810;
英文別名	Famciclovir(104227-87-4);BRL-42810；BRL 42810；BRL42810;2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl diacetate; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol Diacetate; Famciclovir; Amciclovir; Famciclover; FaMtrex; FaMciclovir API; Famvir; famcyclovir; FCV; FaMcivir;1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester) ;9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine;famciclovir;Famvir;
CAS號	104227-87-4
Inchi	InChI = 1S / C14H19N5O4 / c1-9（20）22-6-11（7-23-10（2）21）3-4-19-8-17-12-5-16-14（15）18- 13（12）19 / h5,8,11H，3-4,6-7H2,1-2H3，（H2,15,16,18）
InchiKey	GGXKWVWZWMLJEH-UHFFFAOYSA-N
分子式 Formula	C14H19N5O4
分子量 Molecular Weight	321.33
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 100 mg/mL(311.21 mM)H2O : 50 mg/mL(155.60 mM;Need ultrasonic)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	白色晶體灰白色固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)毒理性質(zhì)：

Famciclovir has been associated with a low rate of serum aminotransferase elevations during oral therapy. In pooled analyses of patients on long term suppressive therapy, 3.2% of famciclovir vs 1.5% of placebo recipients had ALT elevations above twice normal. The elevations were transient and asymptomatic and resolved even without dose modification. Since approval, cases of cholestatic jaundice have been reported to the sponsor, but there have been no published cases. Thus, clinically apparent liver disease due to famciclovir must be rare if it occurs at all.

Likelihood score: E (unlikely cause of clinically apparent liver injury).

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：泛昔洛韋試劑,泛昔洛韋雜質(zhì),泛昔洛韋合成,泛昔洛韋中間體,泛昔洛韋密度,泛昔洛韋溶解度,泛昔洛韋旋光度,泛昔洛韋閃點,泛昔洛韋購買,

產(chǎn)品說明	泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)是一種鳥嘌呤類似物抗病毒藥物,泛昔洛韋用于治療各種皰疹病毒感染C50值.
Introduction	泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections.IC50 Value: Refer to penciclovir
Application1	Famciclovir（BRL 42810）是鳥嘌呤類似物，具有抗皰疹病毒活性。
Application2	泛昔洛韋（Famvir）是鳥嘌呤類似物抗病毒藥物，用于治療各種皰疹病毒感染，最常見的是帶狀皰疹（帶狀皰疹）。它是噴昔洛韋的前藥形式，具有改善的口服生物利用度。
Application3

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)藥理學：

1、泛昔洛韋是一種前藥，它經(jīng)歷了快速生物轉(zhuǎn)化為活性抗病毒藥噴昔洛韋。Penciclovir是一種抗病毒藥物，對1型單純皰疹病毒（HSV-1）和2型單純皰疹病毒（HSV-2）和水痘帶狀皰疹病毒（VZV）具有抑制活性。因此，皰疹病毒DNA的合成和復制被選擇性抑制。

2、泛昔洛韋是抗病毒藥物噴昔洛韋的二乙酰基6-脫氧前藥類似物?？诜何袈屙f可在體內(nèi)轉(zhuǎn)化為噴昔洛韋三磷酸，后者對皰疹病毒具有活性，包括單純皰疹1和2和水痘帶狀皰疹。該試劑通過競爭性干擾DNA聚合酶來抑制病毒DNA的復制。

3、泛昔洛韋是核酸合成抑制劑可以抑制細胞產(chǎn)生DNA或RNA的化合物。

4、泛昔洛韋是抗病毒劑，可以用于預防或治療病毒性疾病的藥物。它們可能發(fā)揮作用的方式包括通過抑制病毒DNA聚合酶來防止病毒復制。與特定的細胞表面受體結(jié)合并抑制病毒滲透或脫殼；抑制病毒蛋白質(zhì)合成；或阻止病毒組裝的后期。泛昔洛韋是一種核苷類似物和抗病毒劑，用于治療帶狀皰疹和單純皰疹病毒感染。泛昔洛韋與治療期間血清中度至中度血清ALT升高率低相關(guān)，但與臨床上明顯的肝損傷無關(guān)。

5、泛昔洛韋，也稱為泛昔洛韋或BRL-42810，屬于稱為嘌呤和嘌呤衍生物的有機化合物。這些是含有芳香雜環(huán)化合物的嘌呤部分，其上形成有嘧啶稠合到環(huán)型圈咪唑環(huán)。

6、泛昔洛韋是一種用于治療急性帶狀皰疹（帶狀皰疹）的藥物。還用于治療或抑制免疫活性患者的生殖器皰疹復發(fā)和HIV感染患者的復發(fā)性皮膚粘膜單純皰疹感染。泛昔洛韋以固體存在，微溶（在水中）和極弱的酸性（基本上是中性）化合物（基于其pKa）。在多種生物流體（如尿液和血液）中檢測到泛昔洛韋。在細胞內(nèi)，泛昔洛韋主要位于細胞質(zhì)中。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)危害標識：

象形圖
象形圖
信號	Danger
GHS危險說明	Aggregated GHS information provided by 4 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
	H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
	H341 (25%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
	H351 (25%): Suspected of causing cancer [Warning Carcinogenicity]
	H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity]
	Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范說明代碼	P201, P202, P264, P280, P281, P305+P351+P338, P308+P313, P337+P313, P405, and P501
防范說明代碼	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Harrell AW, Wheeler SM, Pennick M, Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Di

Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995 Aug;50(2):396-415.

Trépo C, Jezek P, Atkinson G, Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol. 2000 Jun;32(6):1011-8.

Filer CW, Ramji JV, Allen GD, Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica. 1995 May;25(5):477-90.

Wutzler P, Ulbricht A, F?rber I. Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology. 1997;40(1):15-21.

泛昔洛韋(104227-87-4,Famciclovir,BRL 42810)參考文獻：

1.Interventions for prevention of herpes simplex labialis (cold sores on the lips).
Chi CC1, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Cochrane Database Syst Rev. 2015 Aug 7;8:CD010095. doi: 10.1002/14651858.CD010095.pub2.

BACKGROUND: Herpes simplex labialis (HSL), also known as cold sores, is a common disease of the lips caused by the herpes simplex virus, which is found throughout the world. It presents as a painful vesicular eruption, forming unsightly crusts, which cause cosmetic disfigurement and psychosocial distress. There is no cure available, and it recurs periodically.

2.Treatment of Abdominal Segmental Hernia, Constipation, and Pain Following Herpes Zoster with Paravertebral Block.
Kim S1, Jeon Y. Pain Physician. 2015 Sep-Oct;18(5):E927-9.

Herpes zoster (HZ) most commonly occurs in elderly patients and involves sensory neurons resulting in pain and sensory changes. Clinically significant motor deficits and visceral neuropathies are thought to be relatively rare. A 72-year-old man presented with abdominal segmental hernia, constipation, and pain following HZ in the left T9-10 dermatome. Sixteen days before presentation, he had developed a painful herpetic rash in the left upper abdominal quadrant. Approximately 10 days after the onset of the rash, constipation occurred and was managed with daily oral medication with bisacodyl 5 mg. In addition, 14 days after the onset of HZ, the patient noticed a protrusion of the left upper abdominal wall. Abdominal x-ray, ultrasound of the abdomen, and electrolyte analysis showed no abnormalities. General physical examination revealed a reducible bulge in his left upper quadrant and superficial abdominal reflexes were diminished in the affected region.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開